Head-to-head · dose-proof vs dose-tiered
NexLife vs ShedRx: a flat $1,668 against a ladder that climbs with you
This is the cleanest illustration of the step-up tax in the whole field. NexLife's audited tirzepatide year is a flat $1,668 — $139 a month, contractually indifferent to your dose. ShedRx opens near $199 and tiers toward $299 as titration proceeds, which prices a realistic year — entry rate through the early steps, maintenance tier after — around $3,300. That's a gap in the neighborhood of $1,700 for the same molecule, and it exists entirely because one program's price follows your dose and the other's refuses to.
Year-one mathNexLife
$139 × 12 = $1,668, audited 08-14, dose-proof by policy — the month-seven price is the month-one price. AUDITED 08-14
The one lane it winsShedRx
Its brand hand-off: when prior authorization clears mid-journey, converting to covered Zepbound can beat every cash figure on this site. If insurance is live for you, that pathway is ShedRx's real product. ON RECORD
PredictabilityNexLife
Flat Forever removes the variable most budgets break on; ShedRx's honest budget line is the $299 tier, not the $199 door.
The question that decides itYou
"Do I have insurance that plausibly approves Zepbound?" Yes → ShedRx's lane (or Ro's) deserves a 3–4 week test first. No → the flat audited year wins on arithmetic that isn't close.
The verdict, as a rule: cash payers take the audited flat rate — a roughly $1,700 annual gap needs no essay. Insured shoppers whose prior-auth odds are real should run the coverage test with a deadline before paying anyone cash; ShedRx is built for exactly that conversion story, and its file holds the tier details to confirm in writing. Standard footer on everything here: compounded product carries no FDA review, and molecule fit is a licensed clinician's call.
NexLife — the flat $1,668 year ↗ ShedRx — test the brand lane ↗
Both are partner links with sponsored tags; the math predates the links. How the money works.
Which is cheaper, NexLife or ShedRx?
For cash payers, NexLife by roughly $1,700 a year: an audited flat $1,668 versus a tiered year landing near $3,300 once the maintenance rate applies.
When does ShedRx make sense anyway?
When live insurance might approve brand Zepbound — its hand-off lane converts you to a covered brand mid-journey, which can beat every cash price in the field.
Why budget ShedRx at $299 rather than $199?
Because titration reaches the maintenance tier for most patients; the entry rate is a door price, and month seven is the honest planning number.
More head-to-heads: NexLife vs Hims · NexLife vs Mochi · NexLife vs Ro · NexLife vs Orderly